Article detail · 2015
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
- Year
- 2015
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue Haematologica
- Catalog match (ISSN) Haematologica
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
OpenAlex · English
The European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as the novel standard for the detection of lytic lesions in myeloma (grade 1A). Myeloma patients with adequate renal function and bone disease at diagnosis should be treated with zoledronic acid or pamidronate (grade 1A). Symptomatic patients without lytic lesions on conventional radiography can be treated with zoledronic acid (grade 1B), but its advantage is not clear for patients with no bone involvement on computed tomography or magnetic resonance imaging. In asymptomatic myeloma, bisphosphonates are not recommended (grade 1A). Zoledronic acid should be given continuously, but it is not clear if patients who achieve at least a very good partial response benefit from its continuous use (grade 1B). Treatment with erythropoietic-stimulating agents may be initiated in patients with persistent symptomatic anemia (hemoglobin <10g/dL) in whom other causes of anemia have been excluded (grade 1B). Erythropoietic agents should be stopped after 6-8 weeks if no adequate hemoglobin response is achieved. For renal impairment, bortezomib-based regimens are the current standard of care (grade 1A). For the management of treatment-induced peripheral neuropathy, drug modification is needed (grade 1C). Vaccination against influenza is recommended; vaccination against streptococcus pneumonia and hemophilus influenza is appropriate, but efficacy is not guaranteed due to suboptimal immune response (grade 1C). Prophylactic aciclovir (or valacyclovir) is recommended for patients receiving proteasome inhibitors, autologous or allogeneic transplantation (grade 1A).
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
992 citations
OpenAlex cited_by_count (cache / database)
8 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- The Effect of Kinesio Taping on Muscle Pain Sprint Performance and Flexibility in Recovery from Squat Exercise in Young Adult Women 2016
- Xanthogranulomatous Pyelonephritis. 2016
- Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives 2023
- PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma 2019
- The Role of Imaging and Systemic Treatments in Myeloma: A Primer for Radiologists 2020
- Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic 2021
- Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic 2021
- Clinical Presentation and Treatment Outcomes of a Rare Hematologic Malignancy, Solitary Plasmacytoma: Single Center Experience 2022